Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-27T07:18:34.315Z Has data issue: false hasContentIssue false

Chapter 35 - Malignant Disease of Uterine Corpus

from Section 8 - Uterus

Published online by Cambridge University Press:  24 November 2021

By
Nuno Nogueira Martins  and
Ângela Melo
Edited by
Tahir Mahmood ,
Charles Savona-Ventura ,
Ioannis Messinis  and
Sambit Mukhopadhyay
Tahir Mahmood
Affiliation:
Victoria Hospital, Kirkcaldy
Charles Savona-Ventura
Affiliation:
University of Malta, Malta
Ioannis Messinis
Affiliation:
University of Thessaly, Greece
Sambit Mukhopadhyay
Affiliation:
Norfolk & Norwich University Hospital, UK
Get access

Summary

Malignant disease of uterine corpus is mostly represented by endometrial cancer, the most frequent genital tract neoplasia in developed countries, affecting women more frequently in perimenopause or after menopause.

Classically divided into type I endometrioid tumours (80–90%) and type II tumours, associated with a worse prognosis (e.g. serous, clear cell), it recently became clear that the genomic analysis of these tumours is the most accurate tool to recognize the prognosis of an endometrial neoplasia much earlier.

The diagnosis usually involves a combination of ultrasound and hysteroscopy, and the latter remains the gold standard to obtain an endometrial sample in this setting. The standard treatment and extension of the surgical staging will depend on the pre- and perioperative evaluation, including the histological type and grade, as well as the depth of myometrial invasion. The need for adjuvant therapy is currently decided by the assessment of the risk for recurrence.

Keywords

uterushyperplasiacancermalignanttumour
Type
Chapter
Information
The EBCOG Postgraduate Textbook of Obstetrics & Gynaecology
Gynaecology
 , pp. 293 - 304
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ayhan, A, Reed, N, Gultenkin, M, Dursun, P. Endometrial cancer epidemiology & treatment. In: Textbook of Gynaecological Oncology, 3rd edition. Ankara: Günes Publishing, 2016, pp. 529–538.Google Scholar
Colombo, N, Creutzberg, C, Amant, F, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer. Int J Gynecol Cancer 2016;26:2–30.Google Scholar
Setiawan, VW, Yang, HP, Pike, MC, et al. Type I and II endometrial cancers: have they different risk factors? JCO 2013;31:2607–2618.Google Scholar
Ayhan, A, Reed, N, Gultenkin, M, Dursun, P. Endometrial hyperplasia without atypia and endometrioid intraepithelial neoplasia (EIN). In: Textbook of Gynaecological Oncology, 3rd edition. Ankara: Günes Publishing, 2016, pp. 509–515.Google Scholar
RCOG. Management of endometrial hyperplasia. Green-top Guideline No. 67. 2016. Available at : www.rcog.org.uk/globalassets/documents/guidelines/green-top-guidelines/gtg_67_endometrial_hyperplasia.pdf.Google Scholar
Berek, JS. Berek & Novak’s Gynecology, 15th edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2014.Google Scholar
Morice, P, Leary, A, Creutzberg, C, Abu-Rustum, N, Darai, E. Endometrial cancer. Lancet 2018;387:1094–1108.Google Scholar
Iijima, M, Banno, K, Okawa, R, et al. Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer. Oncol Lett 2018;13:1063–1070.Google Scholar
Talhouk, A, McAlpine, JN. New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care. Gynaecol Oncol Res Pract 2018;3:14.Google Scholar
Ayhan, A, Reed, N, Gultenkin, M, Dursun, P. Use of preoperative biomarkers to identify high risk endometrial carcinoma patients. In: Textbook of Gynaecological Oncology, 3rd edition. Ankara: Günes Publishing, 2016, pp. 653–659.Google Scholar
Ayhan, A, Reed, N, Gultenkin, M, Dursun, P. Histopathology of endometrioid endometrial cancer. In: Textbook of Gynaecological Oncology, 3rd edition. Ankara: Günes Publishing, 2016, pp. 539–542.Google Scholar
Ayhan, A, Reed, N, Gultenkin, M, Dursun, P. Uterine serous carcinomas. In: Textbook of Gynaecological Oncology, 3rd edition. Ankara: Günes Publishing, 2016, pp. 565–579.Google Scholar
Ayhan, A, Reed, N, Gultenkin, M, Dursun, P. Uterine clear cell carcinomas. In: Textbook of Gynaecological Oncology, 3rd edition. Ankara: Günes Publishing, 2016, pp. 579–585.Google Scholar
Colombo, N, Preti, E, Landoni, F, et al. Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;24:vi33–vi38.Google Scholar
Munro, M. Investigation of women with postmenopausal uterine bleeding: clinical practice recommendations. Perm J 2014;18:55–70.CrossRefGoogle ScholarPubMed
Koutlaki, N, Dimitraki, M, Zervoudis, S, et al. Hysteroscopy and endometrial cancer: diagnosis and influence on prognosis. Gynecol Surg 2018;7:335–341.CrossRefGoogle Scholar
Frühauf, F, Zikan, M, Semeradova, I, et al. The diagnostic accuracy of ultrasound in assessment of myometrial invasion in endometrial cancer: subjective assessment versus objective techniques. Bio Med Res Int 2017. doi: 10.1155/2017/1318203.CrossRefGoogle Scholar
Nougaret, S, Horta, M, Sala, E, et al. Endometrial cancer MRI staging: updated guidelines of the European Society of Urogenital Radiology. Eur Radiol 2018;29:792–705.CrossRefGoogle ScholarPubMed
Pecorelli, S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynecol Obstet 2009;105:103–104.Google Scholar
Ayhan, A, Reed, N, Gultenkin, M, Dursun, P. Conservative treatment of early endometrial cancer. In: Textbook of Gynaecological Oncology, 3rd edition. Ankara: Günes Publishing, 2016, pp. 586–593.Google Scholar
Stephan, J-M, Hansen, J, Samuelson, M, et al. Intra-operative frozen section results reliably predict final pathology in endometrial cancer. Gynecologic Oncol 2018;133:499–405.Google Scholar
Cripe, J, Handorf, E, Brown, J, et al. National Cancer Database report of lymphadenectomy trends in endometrial cancer. Int J Gynecol Cancer 2017;27:1408–1415.Google Scholar
Ramirez, PT, Frumovitz, M, Abu-Rustum, NR. Principles of Gynecologic Oncology Surgery. Philadelphia, PA: Elsevier, 2018.CrossRefGoogle Scholar
Holloway, RW, Abu-Rustum, NR, Backes, FJ, et al. Sentinel lymph node mapping and staging in endometrial cancer: a Society of Gynecologic Oncology literature review with consensus recommendations. Gynecologic Oncol 2017;146:405–415.Google Scholar
Bodurtha Smith, AJ, Fader, AN, Tanner, EJ. Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis. Am J Obstet Gynecol 2017;216:459–476.e10.CrossRefGoogle ScholarPubMed
Piovano, E, Fuso, L, Poma, CB, et al. Complications after the treatment of endometrial cancer. Int J Gynecol Cancer 2014;24:418–426.Google Scholar
Viswanathan, AN, Lee, LJ, Eswara, JR, et al. Complications of pelvic radiation in patients treated for gynecologic malignancies. Cancer 2014;120:3870–3883.Google Scholar
de Boer, SM, Powell, ME, Mileshkin, L, et al. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 2016;17:1114–1126.Google Scholar
Zhang, Y, Zhao, D, Gong, C, et al. Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis. World J Surg Oncol 2015;13.Google Scholar
Karnezis, AN, Leung, S, Magrill, J, et al. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification. J Path Clin Res 2017;3:279–293.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×